T. Rowe Price Investment Management, Inc. Iovance Biotherapeutics, Inc. Transaction History
T. Rowe Price Investment Management, Inc.
- $166 Billion
- Q3 2024
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Iovance Biotherapeutics, Inc. stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 5,861,279 shares of IOVA stock, worth $43.9 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
5,861,279
Previous 2,050,500
185.85%
Holding current value
$43.9 Million
Previous $16.4 Million
234.66%
% of portfolio
0.03%
Previous 0.01%
Shares
3 transactions
Others Institutions Holding IOVA
# of Institutions
313Shares Held
237MCall Options Held
3.77MPut Options Held
1.7M-
Vanguard Group Inc Valley Forge, PA27.3MShares$205 Million0.0% of portfolio
-
Perceptive Advisors LLC New York, NY26.6MShares$199 Million6.53% of portfolio
-
Mhr Fund Management LLC New York, NY24MShares$180 Million28.52% of portfolio
-
Black Rock Inc. New York, NY21.2MShares$159 Million0.0% of portfolio
-
State Street Corp Boston, MA13.2MShares$98.9 Million0.01% of portfolio
About IOVANCE BIOTHERAPEUTICS, INC.
- Ticker IOVA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 157,800,992
- Market Cap $1.18B
- Description
- Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...